Your browser doesn't support javascript.
loading
Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung Cancer.
Gobbini, Elisa; Pilotto, Sara; Pasello, Giulia; Polo, Valentina; Di Maio, Massimo; Arizio, Francesca; Galetta, Domenico; Petrillo, Patrizia; Chiari, Rita; Matocci, Roberta; Di Costanzo, Alessandro; Di Stefano, Teresa Severina; Aglietta, Massimo; Cagnazzo, Celeste; Sperduti, Isabella; Bria, Emilio; Novello, Silvia.
Afiliação
  • Gobbini E; Department of Oncology, University of Turin, Azienda Ospedaliero-Universitaria San Luigi Gonzaga, Orbassano, Italy.
  • Pilotto S; Department of Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy. Electronic address: sara.pilotto@univr.it.
  • Pasello G; Department of Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padua, Italy.
  • Polo V; Department of Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padua, Italy.
  • Di Maio M; Department of Oncology, University of Turin, Mauriziano Hospital, Turin, Italy.
  • Arizio F; Department of Oncology, University of Turin, Azienda Ospedaliero-Universitaria San Luigi Gonzaga, Orbassano, Italy.
  • Galetta D; Oncology Unit, Clinical Cancer Center, "Giovanni Paolo II", Bari, Italy.
  • Petrillo P; Oncology Unit, Clinical Cancer Center, "Giovanni Paolo II", Bari, Italy.
  • Chiari R; Oncology Unit, "Santa Maria della Misericordia" Hospital, Perugia, Italy.
  • Matocci R; Oncology Unit, "Santa Maria della Misericordia" Hospital, Perugia, Italy.
  • Di Costanzo A; Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
  • Di Stefano TS; Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
  • Aglietta M; Oncology Unit, Candiolo Institute IRCCS, Candiolo, Italy.
  • Cagnazzo C; Oncology Unit, Candiolo Institute IRCCS, Candiolo, Italy.
  • Sperduti I; Department of Biostatistics, Regina Elena National Cancer Institute, Rome, Italy.
  • Bria E; Department of Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.
  • Novello S; Department of Oncology, University of Turin, Azienda Ospedaliero-Universitaria San Luigi Gonzaga, Orbassano, Italy.
Clin Lung Cancer ; 19(2): 191-198, 2018 03.
Article em En | MEDLINE | ID: mdl-29153968
ABSTRACT

INTRODUCTION:

Contract research organization (CRO) support is largely included in clinical trial management, although its effect in terms of time savings and benefit has not yet been quantified. We performed a retrospective multicenter analysis of lung cancer trials to explore differences in term of trial activation timelines and accrual for studies with and without CRO involvement. MATERIALS AND

METHODS:

Results regarding study timelines from feasibility data to first patient enrollment were collected from 7 Italian thoracic oncology departments. The final accruals (screened/enrolled patients) are reported. We considered CRO/sponsor-administered and CRO-free trials according to who was responsible for the management of the crucial setup phases.

RESULTS:

Of 113 trials, 62 (54.9%) were CRO-administered, 34 (30.1%) were sponsor-administered, and 17 (15.0%) were CRO-free. The median time from feasibility invitation to documentation obtainment was 151 days in the CRO-administered trials versus 128 in the sponsor-administered and 120 in the CRO-free trials. The time from document submission to contract signature was 142 days in the CRO-administered versus 128 in the sponsor-administered and 132 in the CRO-free trials. The time from global accrual opening to first patient enrollment was 247 days for the CRO-administered versus 194 in the sponsor-administered and 151 in the CRO-free trials. No significant differences were observed in terms of the median overall timeline 21 months in the CRO-administered, 15 in the sponsor-administered, and 18 months in the CRO-free studies (P = .29).

CONCLUSION:

Although no statistically significant differences were identified, the results of our analysis support the idea that bureaucratic procedures might require more time in CRO-administered trials than in sponsor-administered and CRO-free studies. This bureaucratic delay could negatively affect Italian patients' screening and enrollment compared with other countries.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fluoreto de Sódio / Uretana / Serviços Contratados / Academias e Institutos / Neoplasias Pulmonares / Oncologia Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fluoreto de Sódio / Uretana / Serviços Contratados / Academias e Institutos / Neoplasias Pulmonares / Oncologia Idioma: En Ano de publicação: 2018 Tipo de documento: Article